Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

9.81USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$9.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,485
52-wk High
$23.27
52-wk Low
$9.77

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Inc Files For Stock Shelf Of Up To $250 Million
Tuesday, 6 Nov 2018 05:26pm EST 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION .  Full Article

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
Tuesday, 6 Nov 2018 04:05pm EST 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.37.Q3 EARNINGS PER SHARE VIEW $-1.15 -- THOMSON REUTERS I/B/E/S.COLLABORATION AND LICENSE REVENUE FOR Q3 OF 2018 DECREASED BY $2.5 MILLION, OR 30%, TO $5.8 MILLION FROM $8.3 MILLION FOR Q3 OF 2017.FIVE PRIME EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE LESS THAN $135 MILLION.NOW ESTIMATES ENDING 2018 WITH APPROXIMATELY $265 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article

Five Prime Therapeutics Names David Smith CFO
Monday, 5 Nov 2018 09:32am EST 

Nov 5 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SAYS DAVID SMITH WILL JOIN CO AS CFO, EFFECTIVE AS OF NOVEMBER 26, 2018 - SEC FILING.FIVE PRIME THERAPEUTICS - EFFECTIVE AS OF NOV 26, 2018, LINDA RUBINSTEIN WILL CEASE TO SERVE AS FIVEPRIME'S INTERIM CFO.  Full Article

Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics
Tuesday, 3 Apr 2018 07:00am EDT 

April 3 (Reuters) - Five Prime Therapeutics Inc ::ONCOLOGY DRUG CANDIDATE BEMARITUZUMAB.CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES.FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Five Prime Therapeutics Announces Executive Change
Tuesday, 13 Mar 2018 04:05pm EDT 

March 13 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES EXECUTIVE CHANGE.SAYS CFO MARC BELSKY RESIGNED.‍BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018​.  Full Article

Five Prime Reports Q4 Loss Per Share $1.04
Tuesday, 27 Feb 2018 04:05pm EST 

Feb 27 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.04.FIVE PRIME THERAPEUTICS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $292.7 MILLION ON DEC 31, 2017 VERSUS $421.7 MILLION ON DECEMBER 31, 2016.  Full Article

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION.  Full Article

Five Prime Therapeutics Submits Investigational New Drug Application For FPA150
Wednesday, 3 Jan 2018 04:05pm EST 

Jan 3 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150.FIVE PRIME THERAPEUTICS INC - ANTICIPATES INITIATING A PHASE 1 TRIAL OF FPA150 DURING FIRST HALF OF 2018.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Tuesday, 19 Dec 2017 04:05pm EST 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Pharmacy benefit managers must face lawsuit over EpiPen prices - judge

Four pharmacy benefit managers must face a lawsuit alleging they breached their duties as administrators of employee health insurance plans' drug benefits by causing Mylan NV to raise the EpiPen allergy medication's price, a federal judge has ruled.